Investors sentiment increased to 1.27 in 2019 Q3. Its up 0.10, from 1.17 in 2019Q2. It is positive, as 32 investors sold Jazz Pharmaceuticals plc shares while 102 reduced holdings. 52 funds opened positions while 118 raised stakes. 48.23 million shares or 4.74% less from 50.63 million shares in 2019Q2 were reported.
Moreover, Caxton L P has 0.08% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 3,274 shares. Gw Henssler Assoc holds 0.03% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 2,700 shares. 31,300 are owned by Sector Pension Invest Board. Invesco holds 0.01% or 210,685 shares. Amundi Pioneer Asset Mngmt holds 140,158 shares or 0% of its portfolio. Andra Ap reported 35,700 shares. State Board Of Administration Of Florida Retirement holds 78,741 shares. Allworth Fincl Lp owns 3 shares. Missouri-based Parkside Savings Bank And Tru has invested 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Willingdon Wealth Mgmt holds 7 shares or 0% of its portfolio. Advsrs Asset Mgmt reported 5,042 shares. First Allied Advisory Service Incorporated has invested 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Legal And General Gru Public Ltd Co reported 0.02% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Swiss Savings Bank invested in 0.03% or 187,155 shares. Epoch Inv Ptnrs Inc, a New York-based fund reported 25,054 shares.
The stock of Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) registered an increase of 10.97% in short interest. JAZZ’s total short interest was 2.24 million shares in December as published by FINRA. Its up 10.97% from 2.02 million shares, reported previously. With 499,000 shares average volume, it will take short sellers 5 days to cover their JAZZ’s short positions. The short interest to Jazz Pharmaceuticals Plc – Ordinary Shares’s float is 4.08%.
The stock increased 0.92% or $1.36 during the last trading session, reaching $149.46. About 409,676 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has declined 19.23% since December 8, 2018 and is downtrending. It has underperformed by 19.23% the S&P500.
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $8.55 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 14.32 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage
Among 4 analysts covering Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Jazz Pharmaceuticals plc – Ordinary Shares has $20000 highest and $14200 lowest target. $169.50’s average target is 13.41% above currents $149.46 stock price. Jazz Pharmaceuticals plc – Ordinary Shares had 9 analyst reports since June 11, 2019 according to SRatingsIntel. As per Wednesday, August 21, the company rating was downgraded by Piper Jaffray. The stock has “Market Perform” rating by Bernstein on Monday, October 14. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) earned “Outperform” rating by Wells Fargo on Tuesday, December 3. The rating was maintained by Barclays Capital on Monday, December 2 with “Overweight”.
More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Finance.Yahoo.com which released: “Is Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) CEO Paid At A Competitive Rate? – Yahoo Finance” on November 19, 2019, also Livetradingnews.com with their article: “The Streetâ€™s Key Stock Analysts Research Report – Live Trading News” published on December 03, 2019, Globenewswire.com published: “TowerJazz to Maintain its TPSCo Majority Ownership, Control and Manufacturing Activity – GlobeNewswire” on December 02, 2019. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: Nasdaq.com and their article: “Endo’s (ENDP) BLA for Cellulite Treatment Accepted by FDA – Nasdaq” published on November 21, 2019 as well as Nasdaq.com‘s news article titled: “3 Reasons Growth Investors Will Love Jazz (JAZZ) – Nasdaq” with publication date: December 03, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.